After a new version of an old drug gets orphan status, the price skyrockets

After a new version of an old drug gets orphan status, the price skyrockets

STAT Plus: After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

By ED SILVERMAN

ADOBE

“This seems to be a poor application of the orphan drug law, in my opinion," says Ira Loss of Washington Analysis "How does that qualify as an orphan drug?"

READ MORE